Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
DETROL LA
Generic name / active ingredient
tolterodine tartrate extended-release capsules
Dosage-form class
Tolterodine tartrate extended-release oral capsules: 2 mg or 4 mg per capsule; the label says to swallow whole with liquid; not an immediate-release tolterodine tablet, fesoterodine extended-release tablet or another bladder medicine
Route
Oral
Record reviewed
2026-08-29

Copy from the pack in hand

Source-linked reading points

  • 2 mg and 4 mg are labelled amounts per capsule, while 30 is the bottle count. Although two 2 mg numbers add to 4 mg, that does not permit self-assembling capsules, changing an amount, replacing a 4 mg product, making up a dose or copying another person's prescription.
  • Swallow the capsule whole with liquid. The label does not turn capsule appearance, lack of a score or ‘extended release’ into permission to open, chew, crush, divide or sprinkle it. For swallowing difficulty, take the exact pack and prescription to a pharmacist or prescriber for an appropriate plan.
  • Dry mouth, constipation, abdominal pain, blurred vision, dizziness or drowsiness are important label adverse-effect cues. Older adults, people with cognitive impairment or fall risk, and those using sleeping, allergy, nausea, bladder or other anticholinergic medicines need priority review of the complete medicine list.
  • Urinary retention, gastric retention and uncontrolled narrow-angle glaucoma are labelled contraindications. Gastrointestinal obstruction or reduced motility, myasthenia gravis, liver or kidney impairment and a history of QT prolongation also need to be disclosed.

Reviewed presentation examples — compare every field

  • Tolterodine tartrate 2 mg per capsule; 30-capsule bottle; this package record has a marketing end date of 31 Jul 2026NDC 58151-103-93
  • Tolterodine tartrate 4 mg per capsule; 30-capsule bottle; this package record has a marketing end date of 31 Jul 2026NDC 58151-104-93

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-29
Source record
4 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image